Galixir Investor

Founded in 2019, Galixir is a company dedicated to applying cutting-edge artificial intelligence technologies to empower drug discovery. Integrating tools and experience of computational chemistry, medicinal chemistry and biology, Galixir leverages cutting-edge AI algorithms to resolve problems in preclinical development of small molecule drugs and find candidate molecules with high potency, good druggability and novel structures.

Last Funding Type: Series A
Headquarters: Shenzhen, Guangdong, China
Investor Type: For Profit
Total Funding: 10000000.0
Employee Number: 28
Funding Status: Early Stage Venture
Industry: DeepTech
Technology: AI for Longevity
Estimated Revenue: $1M to $10M
Last Funding Date: 2020-12-29
Founded Date: 2019-01-01
Investors Number: 4.0